Thailand
Tuberculosis profile
| High TB burden | High HIV burden |
Population  2013 67 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 8.1 (4.9–12) 12 (7.3–18)
Mortality (HIV+TB only) 1.9 (1.3–2.4) 2.8 (2–3.6)
Prevalence  (includes HIV+TB) 100 (48–170) 149 (72–252)
Incidence  (includes HIV+TB) 80 (71–90) 119 (106–134)
Incidence (HIV+TB only) 12 (10–13) 17 (15–19)
Case detection, all forms (%) 80 (71–89)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2 (1.4–2.8) 19 (14–25)
MDR-TB cases among notified pulmonary
TB cases
1 000 (730–1 500) 880 (640–1 200)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 32 887   1 802
Pulmonary, clinically diagnosed 19 559   0
Extrapulmonary 9 293   0
       
Total new and relapse 63 541    
Previously treated, excluding relapses 2 874    
Total cases notified 66 415    
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 3 246 (10%) 540 (12%) 3 866
Laboratory-confirmed RR-/MDR-TB cases     230
Patients started on MDR-TB treatment     230
TB/HIV 2013 Number (%)
TB patients with known HIV status 54 991 (83)
HIV-positive TB patients 8 245 (15)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 206 (63)
HIV-positive TB patients on antiretroviral therapy (ART) 4 890 (59)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 81
Previously treated cases, excluding relapse, registered in 2012 63
HIV-positive TB cases, all types, registered in 2012 70
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 4.8
Drug susceptibility testing (per 5 million population) 1.3
Sites performing Xpert MTB/RIF 14
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 16
% Funded domestically 54%
% Funded internationally 33%
% Unfunded 13%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-29 Data: www.who.int/tb/data